Correspondence re: Long-term efficacy and safety of cow's milk anaphylaxis specific immunotherapy: Allergen unresponsiveness via the Tolerance Induction Program

Long-term efficacy and safety of cow's milk anaphylaxis specific immunotherapy: Allergen unresponsiveness via the Tolerance Induction ProgramTo the Editor:I read with incredulity the report by Randhawa and Marsteller, 1 on treatment of 214 patients diagnosed with milk allergy by a method termed the ''Tolerance Induction Program.''The report provides only limited information about the study subjects.For example, the level of cow's milk-specific IgE is reported for only 141 of 214 subjects.Randhawa and Marsteller 1 do not provide sufficient explanation or detail to allow readers to assess the novel methods for categorizing patients (ie, endotyping), determining treatment regimens (vaguely described as using machine learning and boosting analytics), and the treatment regimens themselves (ie, dosing protocols for the foods used in the desensitization process), let alone attempt to validate the report by replicating the findings.The reference-provided machine learning algorithms for the Tolerance Induction Program, 2 do not provide sufficient information to evaluate the validity of the process.Trust is a crucial element of scientific communication.Readers are expected to trust reviewers and editors to adhere to accepted standards of scientific reporting.A fundamental standard is that a report contain sufficient information to allow other scientists to replicate the findings. 3The publication by Randhawa and Marsteller 1 does not meet that standard.